Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open-Label, Single-Group, Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients.

NCT00993967 is registered in ClinicalTrials.gov with Santhera Pharmaceuticals as lead sponsor.

NCT NCT00993967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00993967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open-Label, Single-Group, Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients.
Lead sponsor
Santhera Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2007
Completion date
June 30, 2012
Enrollment
200 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

freidreich's ataxia